PVLA — Palvella Therapeutics, Inc. stock price, charts and financials

QT66Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc. (NASDAQ: PVLA) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
150.56
-3.76-2.44%
OverviewShort InterestFilings
PVLAQT66Palvella Therapeutics, Inc.·NASDAQ
150.56-2.44%
TA
Loading chart...
Signal & projected range
Insider selling clusterHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
AUPH-0.35%$16.90OCUL-1.48%$9.99GENB+0.12%$17.14SLS-0.35%$11.49BCRX-0.23%$8.68SRPT-2.71%$20.11TRVI-1.71%$14.95URGN-1.59%$43.25
Snapshot
Index-P/E-EPS (ttm)-21.79Insider Own13.13%Shs Outstand14.34MPerf Week0.29%
Market Cap2.17BForward P/E-EPS next Y-8.31Insider Trans-2.82%Shs Float9.62MPerf Month0.40%
Enterprise Value2.11BPEG-EPS next Q-1.73Inst Own-Short Float23.81%Perf Quarter33.12%
Income-25.00MP/S50.22EPS this Y69.88%Inst Trans-Short Ratio8.93Perf Half Y32.17%
Sales43.00MP/B55.37EPS next Y-26.60%ROA-24.34%Short Interest2.29MPerf YTD43.84%
Book/sh2.72P/C33.74EPS next 5Y-ROE-47.84%52W High161.37 -6.70%Perf Year166.15%
Cash/sh4.46P/FCF-EPS past 3/5Y-ROIC-23.88%52W Low56.22 167.81%Perf 3Y-
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility3.41% 4.32%Perf 5Y-
Dividend TTM-EV/Sales49.10EPS Y/Y TTM-178.29%Oper. Margin0.00%ATR (14)6.64Perf 10Y-
Dividend Ex-Date-Quick Ratio21.18Sales Y/Y TTM-Profit Margin0.00%RSI (14)49.81Recom1.92
Dividend Gr. 3/5Y-Current Ratio21.18EPS Q/Q-105.41%SMA20-0.38%Beta1.70Target Price232.25
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA500.92%Rel Volume2.68Prev Close154.32
Employees29LT Debt/Eq0.27EarningsNov 10SMA20024.00%Avg Volume236.43KPrice150.56
IPO DateJan 02, 2015Option/ShortYes / YesEPS/Sales Surpr.-29.55% -Net Debt/EBITDA3.75Volume633,629Change-2.44%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-05-26ReiteratedTruist FinancialBuy$210 → $207
Aug-05-26ReiteratedCanaccord GenuityBuy$227 → $232
Jul-22-26ReiteratedH.C. WainwrightBuy$255 → $270
May-12-26InitiatedStephensOverweight$220
Feb-24-26ReiteratedTruist FinancialBuy$190 → $210
Feb-24-26ReiteratedStifel Nicolaus$180 → $250
Feb-24-26ReiteratedChardan CapitalBuy$174 → $210
Feb-24-26ReiteratedHC Wainwright & Co.Buy$200 → $255
Jan-07-26InitiatedMizuhoOutperform$205
Dec-16-25ReiteratedRaymond JamesStrong Buy$143 → $193
Latest News· Times ET
Sep-09-26
Sep-09-2607:30AM
Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical OfficerYahoo
03:30AM
Palvella Therapeutics Appoints James R. Treat, M.D.globenewswire.com
Sep-02-26
Sep-02-2603:30AM
Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferencesglobenewswire.com
Aug-31-26
Aug-31-2603:30AM
Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformationsglobenewswire.com
Aug-29-26
Aug-29-2612:38AM
Bank of America Corp DE Has $4.73 Million Holdings in Palvella Therapeutics, Inc. $PVLAdefenseworld.net
Aug-18-26
Aug-18-2607:11PM
Palvella Therapeutics: First Approval Could Unlock A Rare-Disease Commercial Flywheelseekingalpha.com
Aug-16-26
Aug-16-2608:03AM
Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expandsmarketbeat.com
Aug-05-26
Aug-05-2611:09PM
Palvella Therapeutics Q2 Earnings Call Highlightsdefenseworld.net
07:41AM
Palvella Therapeutics, Inc. 2026 Q2 - Results - Earnings Call PresentationSeekingAlpha
03:30AM
Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conferenceglobenewswire.com
Aug-04-26
Aug-04-2611:50AM
Palvella Therapeutics, Inc. (PVLA) Q2 2026 Earnings Call Transcriptseekingalpha.com
09:05AM
Palvella Therapeutics Q2 Earnings Call Highlightsmarketbeat.com
03:30AM
Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updateglobenewswire.com
Aug-01-26
Aug-01-2612:11AM
Arete Wealth Advisors LLC Makes New $2.18 Million Investment in Palvella Therapeutics, Inc. $PVLAdefenseworld.net
Jul-30-26
Jul-30-2603:30AM
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposingglobenewswire.com
Company

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
Total Revenue
4300———
Cost of Goods Sold Incl. D&A
300———
Gross Profit
4000———
Selling, General and Administrative Excl. Other16166———
Research and Development41238———
Other Operating Expense
000———
Operating Income-16-39-14———
Interest Expense064———
Unusual Expense
——————
Non-Operating Income (Expense)-931———
Net Income Before Taxes-25-42-17———
Income Taxes
000———
Consolidated Net Income-25-42-17———
Net Income From Continuing Operations-25-42-17———
Net Income-25-42-17———
EPS (Recurring)-21.80-3.71-7.83———
EPS (Basic, Before Extraordinaries)-21.80-3.71-7.83———
EPS (Diluted)-21.79-3.71-7.83———
EBITDA-23-36-13———
Other After Tax Adjustments
——————
Stock Option Compensation Expense
——————
Price To Earnings Ratio
——————
Price To Sales Ratio
3.50—————
Gross Margin
93.02—————
Operating Margin
-37.21—————
Net Margin
-58.14—————
Shares Outstanding1112———
Market Capitalization1511,15124———
Operating Lease Expense
——————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$177.47$134.79$92.11$49.44$6.76● Close Price0.00M1.22M2.44M3.65M4.87MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Goin KathleenChief Operating OfficerSep 16 '26Sale152.244,302654,9240Sep 18
Goin KathleenChief Operating OfficerSep 16 '26Option Exercise8.114,30234,8844,302Sep 18
JENKINS GEORGE MDirectorSep 15 '26Sale150.141,777266,806160,116Sep 15
JENKINS GEORGE MDirectorSep 14 '26Sale151.9613,3522,028,905161,893Sep 15
JENKINS GEORGE MDirectorSep 11 '26Sale151.2812,3711,871,435175,245Sep 15
KIRITSY CHRISTOPHER PDirectorSep 02 '26Option Exercise127.2031339,814563Sep 04
KIRITSY CHRISTOPHER PDirectorSep 02 '26Sale157.0031349,141250Sep 04
Goin KathleenChief Operating OfficerAug 19 '26Option Exercise8.114,30234,8844,302Aug 20
Goin KathleenChief Operating OfficerAug 19 '26Sale152.214,302654,7910Aug 20
Goin KathleenChief Operating OfficerJul 15 '26Sale149.284,302642,1910Jul 17
Goin KathleenChief Operating OfficerJul 15 '26Option Exercise8.114,30234,8844,302Jul 17
Goin KathleenChief Operating OfficerJun 17 '26Option Exercise8.114,30234,8844,302Jun 22
Goin KathleenChief Operating OfficerJun 17 '26Sale110.734,302476,3730Jun 22
Korenberg Matthew ECFO, TreasurerJun 12 '26Option Exercise13.601,00013,6001,000Jun 16
Goin KathleenChief Operating OfficerMay 20 '26Option Exercise8.114,30234,8844,302May 22
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.